• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

    10/24/23 5:00:55 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MEIP alert in real time by email
    SC 13D/A 1 sc13da713392004_10242023.htm AMENDMENT NO. 7 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 7)1

    MEI Pharma, Inc.

    (Name of Issuer)

    Common Stock, $0.00000002 par value

    (Title of Class of Securities)

    55279B202

    (CUSIP Number)

    JACOB MA-WEAVER

    CABLE CAR CAPITAL LLC

    601 California Street, Suite 1151

    San Francisco, California 94108

    (415) 857-1965

    BRUCE R. WINSON

    ANSON FUNDS MANAGEMENT LP

    16000 Dallas Parkway, Suite 800

    Dallas, Texas 75248

    (214) 866-0202

     

    ANDREW FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    October 20, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 55279B202

      1   NAME OF REPORTING PERSON  
             
            Funicular Funds, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         611,440  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              611,440  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            611,440  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            9.2%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 55279B202

      1   NAME OF REPORTING PERSON  
             
            Cable Car Capital LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            California  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         611,440  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              611,440  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            611,440  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            9.2%  
      14   TYPE OF REPORTING PERSON  
             
            IA, OO  

      

    3

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Jacob Ma-Weaver  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         611,440  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              611,440  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            611,440  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            9.2%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    4

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson Investments Master Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         841,674  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              841,674  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            841,674  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            12.6%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    5

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            AIMF GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         841,674  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              841,674  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            841,674  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            12.6%  
      14   TYPE OF REPORTING PERSON  
             
            HC, OO  

      

    6

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson East Master Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         214,304  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              214,304  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            214,304  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            3.2%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    7

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            AEMF GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         214,304  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              214,304  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            214,304  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            3.2%  
      14   TYPE OF REPORTING PERSON  
             
            HC, OO  

      

    8

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson Opportunities Master Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         37,210  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              37,210  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            37,210  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    9

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            AOMF GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         37,210  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              37,210  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            37,210  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            HC, OO  

      

    10

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson Funds Management LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            IA, PN  

      

    11

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson Management GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            HC, OO  

      

    12

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Bruce R. Winson  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    13

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Anson Advisors Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Ontario, Canada  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            FI, CO  

      

    14

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Amin Nathoo  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Canada  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    15

    CUSIP No. 55279B202

     

      1   NAME OF REPORTING PERSON  
             
            Moez Kassam  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Canada  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         1,093,188  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              1,093,188  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,093,188  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.4%  
      14   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    16

    CUSIP No. 55279B202

    The following constitutes Amendment No. 7 to the Schedule 13D filed by the undersigned (“Amendment No. 7”). This Amendment No. 7 amends the Schedule 13D as specifically set forth herein. Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D. The beneficial ownership reported herein has been rounded to the nearest whole share, as applicable.

    Item 3.Source and Amount of Funds or Other Considerations

    Item 3 is hereby amended and restated to read as follows:

    The Shares of the Issuer purchased by Funicular were acquired for an aggregate purchase price of approximately $3,817,921 inclusive of brokerage commissions. Funds for the purchase were obtained from the available working capital of Funicular. Although Funicular has the ability to obtain margin loans in the ordinary course of its business, no part of the purchase price was obtained on margin or through any other borrowings.

    The Shares of the Issuer purchased by Anson Master were acquired for an aggregate purchase price of approximately $9,548,967 inclusive of brokerage commissions. Although Anson Master has the ability to obtain margin loans in the ordinary course of its business, no part of the purchase price was obtained on margin or through any other borrowings.

    The Shares of the Issuer purchased by Anson East Master were acquired for an aggregate purchase price of approximately $2,521,660 inclusive of brokerage commissions. Although Anson East Master has the ability to obtain margin loans in the ordinary course of its business, no part of the purchase price was obtained on margin or through any other borrowings.

    The Shares of the Issuer purchased by Anson Opportunities were acquired for an aggregate purchase price of approximately $678,363 inclusive of brokerage commissions. Although Anson Master has the ability to obtain margin loans in the ordinary course of its business, no part of the purchase price was obtained on margin or through any other borrowings.

    Item 5.Interest in Securities of the Issuer

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by the Reporting Persons is based on 6,662,857 shares outstanding as of September 15, 2023, which is the total number of shares outstanding as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 26, 2023.

    As of the close of business on October 24, 2023, Funicular beneficially owned 611,440 Shares, constituting approximately 9.2% of the Issuer’s outstanding Shares. Cable Car, as the general partner of Funicular, may be deemed the beneficial owner of the 611,440 Shares owned by Funicular. Mr. Ma-Weaver, as the Managing Member of Cable Car, may be deemed the beneficial owner of the 611,440 Shares owned by Funicular.

    17

    CUSIP No. 55279B202

    As of the close of business on October 24, 2023, Anson Master may be deemed the beneficial owner of 841,674 Shares, constituting approximately 12.6% of the Issuer’s outstanding Shares. As the general partner of Anson Master, AIMF GP may be deemed to beneficially own the 841,674 Shares beneficially owned by Anson Master. As of the close of business on October 24, 2023, Anson East Master may be deemed the beneficial owner of 214,304 Shares, constituting approximately 3.2% of the Issuer’s outstanding Shares. As the general partner of Anson East Master, AEMF GP may be deemed to beneficially own the 214,304 Shares beneficially owned directly by Anson East Master. As of the close of business on October 24, 2023, Anson Opportunities may be deemed the beneficial owner of 37,210 Shares, constituting less than 1% of the Issuer’s outstanding Shares. As the general partner of Anson Opportunities, AOMF GP may be deemed to beneficially own the 37,210 Shares beneficially owned directly by Anson Opportunities. Each of Anson Management and Anson Advisors, as the co-investment advisors to the Anson Funds, may be deemed the beneficial owner of the 1,093,188 Shares beneficially owned in the aggregate by the Anson Funds, constituting approximately 16.4% of the Issuer’s outstanding Shares. Anson Management GP, as the general partner of Anson Management, may be deemed the beneficial owner of the 1,093,188 Shares beneficially owned by Anson Management. Mr. Winson, as the principal of Anson Management and the managing member of Anson Management GP, may be deemed the beneficial owner of the 1,093,188 Shares beneficially owned by Anson Management. Mr. Nathoo, as a director and the CEO, Secretary and Chief Compliance Officer of Anson Advisors, may be deemed the beneficial owner of the 1,093,188 Shares beneficially owned by Anson Advisors. Mr. Kassam, as a director and the Chief Investment Officer and President of Anson Advisors, may be deemed the beneficial owner of the 1,093,188 Shares beneficially owned by Anson Advisors.

    As of the close of business on October 24, 2023, the Reporting Persons collectively beneficially owned an aggregate of 1,704,628 Shares, constituting approximately 25.6% of the shares of Common Stock outstanding.

    (c)       The transactions in the Shares by the Reporting Persons since the filing of Amendment No. 6 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. All of such transactions were effected in the open market unless otherwise noted therein.

    The filing of this Amendment No. 7 shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the securities reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that are not directly owned by such Reporting Person.

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

    Item 6 is hereby amended to add the following:

    As previously disclosed, each of Anson Master, Anson East Master and Funicular sold exchange-listed American-Style put options, which had an exercise price of $7.00 per Share and expired on October 20, 2023. On October 20, 2023, 143,200 Shares were delivered to Anson Master upon assignment of 1,432 of such put options, 35,800 Shares were delivered to Anson East Master upon assignment of 358 of such put options, and 120,600 Shares were delivered to Funicular upon assignment of 1,260 of such put options, as further detailed on Schedule A attached hereto, which is incorporated by reference herein. Also on October 20, 2023, the remainder of the put options sold by Anson Master, Anson East Master and Funicular, referencing an aggregate of 536,800 Shares, 134,200 Shares and 449,400 Shares, respectively, expired worthless pursuant to their terms and, accordingly, none of Anson Master, Anson East Master and Funicular have any exposure to such put options.

    18

    CUSIP No. 55279B202

    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 24, 2023

      CABLE CAR CAPITAL LLC
       
      By:

    /s/ Jacob Ma-Weaver

        Name: Jacob Ma-Weaver
        Title: Managing Member

     

     

      FUNICULAR FUNDS, LP
       
      By: Cable Car Capital LLC
         
      By:

    /s/ Jacob Ma-Weaver

        Name: Jacob Ma-Weaver
        Title: Managing Member

     

     

     

    /s/ Jacob Ma-Weaver

      JACOB MA-WEAVER

     

     

      ANSON FUNDS MANAGEMENT LP
       
      By: Anson Management GP LLC, its general partner
         
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Manager

     

     

      ANSON MANAGEMENT GP LLC
       
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Manager

     

     

    19

    CUSIP No. 55279B202

      ANSON ADVISORS INC.
       
      By:

    /s/ Amin Nathoo

        Name: Amin Nathoo
        Title: Director
           
      By:

    /s/ Moez Kassam

        Name: Moez Kassam
        Title: Director

     

     

      ANSON INVESTMENTS MASTER FUND LP
       
      By: AIMF GP LLC, its general partner
         
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

      AIMF GP LLC
       
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

      ANSON EAST MASTER FUND LP
       
      By: AEMF GP LLC, its general partner
         
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

      AEMF GP LLC
       
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

    20

    CUSIP No. 55279B202

      ANSON OPPORTUNITIES MASTER FUND LP
       
      By: AOMF GP, LLC, its general partner
         
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

      AOMF GP, LLC
       
      By:

    /s/ Bruce R. Winson

        Name: Bruce R. Winson
        Title: Director

     

     

     

    /s/ Bruce R. Winson

      Bruce R. Winson

     

     

     

    /s/ Amin Nathoo

      Amin Nathoo

     

     

     

    /s/ Moez Kassam

      Moez Kassam

     

    21

    CUSIP No. 55279B202

    SCHEDULE A

    Transactions in Securities of the Issuer Since the Filing of Amendment No. 6 to the Schedule 13D

    Nature of the

    Transaction

    Amount of Securities

    Purchased/(Sold)

    Price ($)

    Date of

    Transaction

     

    ANSON INVESTMENTS MASTER FUND LP

    Acquisition of Common Stock Upon Assignment of October 2023 Put Option ($7 Strike Price) 143,200 7.0000 10/20/2023

     

    ANSON EAST MASTER FUND LP

    Acquisition of Common Stock Upon Assignment of October 2023 Put Option ($7 Strike Price) 35,800 7.0000 10/20/2023

     

    FUNICULAR FUNDS, LP

    Acquisition of Common Stock Upon Assignment of October 2023 Put Option ($7 Strike Price) 120,600 7.0000 10/20/2023

     

    Get the next $MEIP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEIP

    DatePrice TargetRatingAnalyst
    7/23/2024Buy → Hold
    Laidlaw
    3/25/2022$4.00 → $1.00Buy → Hold
    Jefferies
    3/25/2022$13.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    3/25/2022$6.00 → $2.00Buy → Hold
    Stifel
    2/3/2022$4.00Buy
    Jefferies
    More analyst ratings

    $MEIP
    Financials

    Live finance-specific insights

    See more
    • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

      Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

      2/12/25 4:12:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

      Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

      11/12/24 4:05:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Fiscal Year End 2024 Cash Position

      Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

      9/19/24 4:01:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MEIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MEIP
    Leadership Updates

    Live Leadership Updates

    See more

    $MEIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

      SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

      2/14/24 4:00:25 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

      SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

      2/13/24 5:09:37 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

      SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)

      11/1/23 5:20:11 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wood Steven D was granted 3,100 shares, increasing direct ownership by 246% to 4,359 units (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      5/21/24 4:00:05 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James P was granted 7,900 shares (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      5/20/24 4:00:13 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Flynn James P (Amendment)

      4/A - MEI Pharma, Inc. (0001262104) (Issuer)

      1/12/24 4:00:15 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl

      6/13/23 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.

      6/2/23 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

      MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En

      6/22/22 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma downgraded by Laidlaw

      Laidlaw downgraded MEI Pharma from Buy to Hold

      7/23/24 6:35:29 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously

      3/25/22 7:17:08 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously

      3/25/22 7:16:36 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

      Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

      2/12/25 4:12:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

      Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

      11/12/24 4:05:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Fiscal Year End 2024 Cash Position

      Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

      9/19/24 4:01:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MEIP
    SEC Filings

    See more
    • Anson Funds Management Lp bought $329,331 worth of shares (48,060 units at $6.85) (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/25/23 7:43:12 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Funicular Funds, Lp bought $219,554 worth of shares (32,040 units at $6.85) (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/25/23 7:41:22 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Anson Funds Management Lp bought $938,226 worth of shares (153,600 units at $6.11)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/22/23 9:21:02 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MEI Pharma, Inc. (0001262104) (Filer)

      3/7/25 4:30:07 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MEI Pharma, Inc. (0001262104) (Filer)

      2/12/25 4:05:08 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MEI Pharma Inc.

      10-Q - MEI Pharma, Inc. (0001262104) (Filer)

      2/12/25 4:00:20 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care